TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Albiglutide in Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* type 2 diabetes~* BMI 20-45kg/m2~Exclusion Criteria:~* NYHA Class II to IV heart failure~* females who are pregnant, lactating, or less than 6 weeks post-partum

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- placebo + pioglitazone (with or without metformin) (Type: PLACEBO_COMPARATOR): Placebo albiglutide weekly injection + pioglitazone (with or without metformin)
- albiglutide + pioglitazone (with or without metformin) (Type: EXPERIMENTAL): albiglutide weekly injection + pioglitazone (with or without meformin)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Investigate the Clinical Benefits of Dietary Supplement Quercetin for Managing Early Mild Symptoms of COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must be 18 years of age or older, of either gender~* Patients must be tested positive for SARS-CoV-2 by RT-PCR~* Patients must exhibit typical symptoms of COVID-19 disease at screening such as fever, fatigue, a dry and contagious cough, loss of appetite, body aches, shortness of breath, mucus or phlegm, sore throat, headache, chills, sometimes with shaking, loss of smell or taste, congestion or runny nose, nausea, or vomiting, diarrhea, muscular pain etc.~* Patients must be in the early stage of COVID-19 disease who do not require hospitalisation at the time of screening~* Patients must be under the care of a Physician for diagnosis of COVID-19~* Patients who have signed informed consent~Exclusion Criteria:~* Patients with proven hypersensitivity or allergic reaction to quercetin~* Patients with known chronic kidney disease with estimated creatinine clearance \< 50 mL/minute or need for dialysis~* Patients who are severely hypotensive defined as needing hemodynamic pressors to maintain blood pressure~* Patients with moderate or severe thrombocytopenia (platelet count \<100 × 10⁹/L);~* Pregnant patients~* Patients declining to participate

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard of care (SOC) (Type: ACTIVE_COMPARATOR): This arm will receive the standard of care (SOC) for COVID-19 as per the hospital guidelines.
- Quercetin (Type: EXPERIMENTAL): This arm will receive standard of care + oral Quercetin for two weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dose-ranging Study of Nemolizumab in Atopic Dermatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects ≥ 18 years (or legal age when higher)~* Chronic AD, that has been present for at least 2 years before the visit~* Eczema Area and Severity Index (EASI) score ≥12~* Investigator Global Assessment (IGA) score ≥ 3~* AD involvement ≥ 10% of Body Surface Area (BSA)~* Severe pruritus on at least 3 of the last 7 days before the visit~* Documented recent history (within 6 months before the visit) of inadequate response to topical medications~* Female subjects must fulfill one of the criteria below:~  * Female subjects of non-childbearing potential~ * Female subjects of childbearing potential who agree to a true abstinence or to use an effective or highly effective method of contraception throughout the clinical trial and for 120 days after the last study drug administration~Exclusion Criteria:~* Body weight \< 45 kg~* subjects with a medical history of asthma requiring hospitalization in the last 12 months before screening visit and/or whose asthma has not been well-controlled during the last 3 months before the screening visit and/or Peak Expiratory Flow (PEF) \<80% of the predicted value~* Cutaneous bacterial or viral infection within 1 week before the screening visit or during the run-in period~* Infection requiring treatment with oral or parenteral antibiotics, antivirals, antiparasitics or antifungals within 1 week before the screening visit or during the run-in period~* History of intolerance to low or mid potency TCS or for whom TCS is not advisable

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: EXPERIMENTAL): Nemolizumab (low dose)
- Group 2 (Type: EXPERIMENTAL): Nemolizumab (medium dose)
- Group 3 (Type: EXPERIMENTAL): Nemolizumab (high dose)
- Group 4 (Type: PLACEBO_COMPARATOR): Nemolizumab placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Violent First-Person Shooter (FPS) Video Games on Shooting Accuracy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 and older~* Ohio State participant pool~Exclusion Criteria:~* Under age 18

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 46 Years
- Healthy Volunteers: f

Study Arms:
- Pilot Study (Type: EXPERIMENTAL): After giving their consent, participants completed a survey. Next, they were randomly assigned to play either a violent First-Person-Shooter video game or a nonviolent shooting video game for 20 minutes. Video game play was recorded. A debriefing followed.
- Experiment Proper (Type: EXPERIMENTAL): After giving their consent, participants completed a survey. Next, they were randomly assigned to play either a violent First-Person-Shooter video game, a nonviolent shooting video game, or a nonviolent non-shooting video game for 20 minutes. Next, they shot a training pistol at a mannequin 20 feet (6.1 meters) away using 16 Velcro bullets. A debriefing followed.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Prophylactic Norepinephrine Infusion Combined With Colloid Coloading for Postspinal Anesthesia Hypotension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 5.0

Eligibility Criteria:
Criteria: Inclusion Criteria:~* 18-40 years~* Primipara or multipara~* Singleton pregnancy ≥ 37 weeks~* American Society of Anesthesiologists physical status classification I to II~* Scheduled for elective cesarean section under spinal anesthesia~Exclusion Criteria:~* Body height \< 150 cm~* Body weight \> 100 kg or body mass index (BMI) ≥ 40 kg/m2~* Eclampsia or chronic hypertension or baseline blood pressure ≥ 160mmHg~* Hemoglobin \< 7g/dl~* Coagulation or renal function disorders~* Known allergy to hydroxyethyl starch~* Fetal distress, or known fetal developmental anomaly

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Control group (Type: PLACEBO_COMPARATOR): Simultaneous with spinal anesthesia, 500 mL 6% Hydroxyethyl starch (130/0.4) coload was given and a maintenance dose of normal saline by IV infusion.
- 0.025 μg/kg/min group (Type: EXPERIMENTAL): Simultaneous with spinal anesthesia, 500 mL 6% Hydroxyethyl starch (130/0.4) coload was given and a maintenance dose of norepinephrine (0.025 μg/kg/min) by IV infusion.
- 0.05 μg/kg/min group (Type: EXPERIMENTAL): Simultaneous with spinal anesthesia, 500 mL 6% Hydroxyethyl starch (130/0.4) coload was given and a maintenance dose of norepinephrine (0.05 μg/kg/min) by IV infusion.
- 0.075 μg/kg/min group (Type: EXPERIMENTAL): Simultaneous with spinal anesthesia, 500 mL 6% Hydroxyethyl starch (130/0.4) coload was given and a maintenance dose of norepinephrine (0.075 μg/kg/min) by IV infusion.
- 0.1μg/kg/min group (Type: EXPERIMENTAL): Simultaneous with spinal anesthesia, 500 mL 6% Hydroxyethyl starch (130/0.4) coload was given and a maintenance dose of norepinephrine (0.1μg/kg/min) by IV infusion.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: STOPFLU: Is it Possible to Reduce the Number of Days Off in Office Work by Improved Hand-hygiene?

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Volunteers working in defined units~Exclusion Criteria:~* Persons with open wounds or chronic eczema in hands

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Hand washing (Type: ACTIVE_COMPARATOR): Instructions for proper coughing and sneezing, and for reduced hand shaking; frequent hand washing in office and at home
- Disinfectant rubbing (Type: ACTIVE_COMPARATOR): Instructions for proper coughing and sneezing, and for reduced hand shaking; frequent rubbing of hands with alcohol containing disinfectant in office and at home
- Control (Type: NO_INTERVENTION): No change in hygiene behaviour

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Bexarotene Augmentation of Antipsychotic Treatment for Chronic Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 18-60 years, male or female~2. DSM-IV criteria for schizophrenia, or schizoaffective disorder.~3. Ability and willingness to sign informed consent for participation in the study~4. Stable blood parameters including adequate hematologic function, defined as WBC ≥ 4.300/μL, absolute neutrophil count ≥3.000/μL (\> 50%), and platelet count ≥ 180,000/μL; normal coagulation parameters; bilirubin ≤1.5 times the upper limit of normal (ULN); AST/ALT ≤ 2.5 × ULN; and serum creatinine ≤1.5 mg/dL.~5. Only patients who had a normal baseline fasting triglyceride (FTG) level will be entered into the study; triglycerides may be normalized before study entry with use of an antilipemic agent.~Exclusion Criteria:~1. Lipid abnormalities. Fasting triglyceride normal (normalization with an antilipemic allowed prior to study entry).~2. Leucopenia or neutropenia. Hematopoietic: Hemoglobin at least 12.5 g/dL; WBC\< 4300/μL; Absolute neutrophil count \< 3000/μL; Platelet count \< 155,000/μL~3. Evidence of organic brain damage, mental retardation, alcohol or drug abuse~4. Impairment of renal function~5. Hepatic dysfunction~6. A history of pancreatitis~7. Thyroid axis alterations~8. Suicide attempt in past year.~9. Cataracts.~10. Systemic treatment with more than 15,000 IU of vitamin A daily.~11. Patients with a known hypersensitivity to bexarotene or other components of the product.~12. Pregnant women or a woman who intends to become pregnant.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Bexarotene (Targretin LGD1069) (Type: PLACEBO_COMPARATOR): None
- placebo (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: THISTLE - The HIV-HCV Silibinin Trial

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~* Age greater or equal 18 years~* HIV-HCV co-infection~* HCV Genotype 1 infection~* At least one liver biopsy since diagnosis of HCV-infection~* Fibrosis score METAVIR = 2 documented by biopsy OR a stiffness greater or equal 7.0 kPa documented by fibroscan during the previous 12 months.~* Documented previous null-response or partial-response to SOC~Exclusion criteria:~* Contraindications to the study drug under study, e.g. known hypersensitivity or allergy to any ingredient of the study drug~* Patients in need of ART with HIV virological failure (= 400 copies/ml) in the last 3 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ibodutant for Relief of Irritable Bowel Syndrome With Diarrhoea (IBS-D)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~At start of the run-in period:~* Male or female patients aged 18 - 70 years with a clinical diagnosis of IBS-D according to the Rome III criteria:~* Recurrent abdominal pain/discomfort for at least 3 days per month in the last 3 months associated with at least 2 of the following characteristics:~  1. improvement with defecation;~ 2. onset associated with a change in the frequency of stool;~ 3. onset associated with a change in form (appearance) of stool.~* Symptom-onset at least 6 months prior to diagnosis.~* Loose/watery stools at least 25% of the time in the last 3 months AND hard/lumpy stools less than 25% of the time in the last 3 months.~* More than 3 bowel movements per day at least 25% of the time in the last 3 months.~* For patients older than 50 years OR patients with positive family history of colorectal cancer: Normal results from colonoscopy or flexible sigmoidoscopy.~* Mentally competent, able to give written informed consent.~* For women of childbearing potential: Use of a highly effective contraceptive method throughout the entire study period and up to 30 days post-treatment.~* Normal physical examination or without clinically relevant abnormalities.~At randomisation:~-Confirmation of IBS-D severity in terms of bowel movement frequency and abdominal pain intensity along the 2-week run-in period.~Exclusion criteria:~* Organic abnormalities of the gastrointestinal tract, including history of colonic or major abdominal surgery.~* History of gluten enteropathy.~* Lactose intolerance as assessed by response to diet.~* History of positive tests for ova or parasites, or occult blood in the stool.~* Previous diagnosis of diabetes mellitus (either type 1 or 2).~* Unstable medical condition.~* Major psychiatric, neurological, or cardiovascular disorders, or uncontrolled metabolic disease.~* Relevant changes in dietary habits, lifestyle, or exercise regimen in the previous 2 months.~* Use of concurrent medication with drugs known to interfere with gastro-intestinal motility or sensitivity.~* Pregnancy or breastfeeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Ibodutant low dose (Type: EXPERIMENTAL): Oral tablet, to be given once daily in fasting conditions.
- Ibodutant intermediate dose (Type: EXPERIMENTAL): Oral tablet, to be given once daily in fasting conditions.
- Ibodutant high dose (Type: EXPERIMENTAL): Oral tablet, to be given once daily in fasting conditions.
- Placebo (Type: PLACEBO_COMPARATOR): Oral tablet, to be given once daily in fasting conditions.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Open-label Study of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus Patients With Active Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* SL0007 patients who completed through week 12 of the study or who early terminated at week 8 or later due to treatment failure~* Patients must have maintained eligibility requirements throughout their participation in SL0007~* Written informed consent signed prior to initiation of any study-specific assessments at visit 1~Exclusion Criteria:~* Patients may not receive any live vaccination within 2 weeks prior to visit 1 or during the course of the study~* Active severe SLE disease activity which involves the CNS system (defined by BILAG neurologic A level activity) including transverse myelitis, psychosis and seizures~* Active severe SLE disease activity which involves the Renal system (defined by BILAG renal level A activity or Grade III or higher WHO nephritis) or serum creatinine \>2.5mg/dL or clinically significant serum creatinine increase within the prior 4 weeks or proteinuria \>3.5gm/day~* Patients with a history of anti-phospholipid antibody syndrome AND Use of oral anticoagulants or anti-platelet treatment~* Patients with a history of chronic infection, recent significant infection, or any current sign of symptom that may indicate an infection.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- EMAB (Type: EXPERIMENTAL): 1200 mg epratuzumab given in 2 doses every other week in 12 week treatment cycles.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dose-finding of PB-119 Administered Subcutaneously Once-weekly Versus Placebo in Drug-naïve T2DM Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Males and/or females between the ages of ≥18 and ≤70 years at Screening~2. Patients in whom T2DM has been diagnosed according to 1999 WHOT2DM diagnostic criteria~3. HbA1c ≥7.5% and ≤11% at Screening and at Week -1~4. Body mass index (BMI) ≥18.5 and ≤35.0 kg/m2 at Screening~Exclusion Criteria:~1. Female who is pregnant, intends to become pregnant or breast-feeding or is of child-bearing potential and not using adequate contraception methods throughout the trial~2. Treatment with any glucose lowing agent(s) within 3 months prior to screening.An exception is short-term treatment (no longer than 7 days in total) with insulin in connection with inter-current illness~3. Calcitonin ≥50 ng/L at screening~4. Patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia, type 2~5. Fasting triglyceride ≥500 mg/dL at Screening, or patients with a history of lipid disorders taking unstable treatment dosage (eg, statins) within 3 months prior to screening~6. Any acute or chronic condition that, in the opinion of the Investigator, would limit the patient's ability to complete and/or participate in this trial~7. Blood amylase or lipase \>3x ULN, history of acute or chronic pancreatitis, or history of symptomatic gallbladder disease at Screening~8. Serum creatinine ≥1.5 mg/dL (male patients) or ≥1.4 mg/dL (female patients), or estimated glomerular filtration rate (eGFR) \<45 mL/min/1.73 m2 at Screening~9. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>2x upper limit of normal (ULN) at Screening and pre-randomization~10. Severe cardiovascular diseases occurring within 6 months prior to screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- PB-119 75ug (Type: EXPERIMENTAL): PB-119 injection 75ug subcutaneously injected once-weekly for 12 weeks
- PB-119 150ug (Type: EXPERIMENTAL): PB-119 injection 150ug subcutaneously injected once-weekly for 12 weeks
- PB-119 200ug (Type: EXPERIMENTAL): PB-119 injection 200ug subcutaneously injected once-weekly for 12 weeks
- placebo (Type: PLACEBO_COMPARATOR): placebo injection subcutaneously injected once-weekly for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Tramadol Versus Celecoxib for Reducing Pain in Outpatient Hysteroscopy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* women referred to the outpatient hysteroscopy in Cairo university hospitals~* Consent to the procedure~Exclusion Criteria:~* Premenstrual patients~* Patients with missed periods~* Known cardiac disease~* Known gastritis or peptic ulcer~* Known allergy to Tramadol or Celecoxib

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tramadol (Type: ACTIVE_COMPARATOR): Women will receive Tramadol 100mg 1 hour before the procedure.
- Celecoxib (Type: ACTIVE_COMPARATOR): Women will receive Celecoxib 200mg 1 hour before the procedure.
- Placebo (Type: PLACEBO_COMPARATOR): Women will receive a placebo 1 hour before the procedure.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete